Lessons learned in building HTPD capabilities
A workshop to discuss the benefits and pitfalls of establishing in-house HTPD workflows and equipment.
Intention of Workshop Content
The workshop included short presentations by scientists followed by a panel discussion. Topics included method development, industry benchmarking, HTPD successes and failures, what workflows were most and least appropriated to automate, and how HTPD predictions could fit with scale-up executions.
|15.00 — 15.20||Part I||Introduction by Ashley Hesslein, PhD
Senior Scientist, Global Biological Development
|15.20 — 16.10||Part II||Short presentations by panelists|
|16.10 — 18.00||Part III||Open discussion between panelists and audience|
|Biopharma Process Science Downstream
Sr. Research Scientist
|Virology and Purification Development
Eli Lilly and Company
Genentech, San Francisco California
|Process Development and Engineering
Merck, Kenilworth New Jersey
|David C. Smithson, Ph.D.
|Early Stage Pharmaceutical Development
Genentech, San Francisco, California